NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

ViCentra lands $13M, pushing Kaleido insulin pump funding to $98M

ViCentra pump
Image credits: ViCentra

For people living with diabetes, managing insulin therapy is a demanding part of daily life. Traditional insulin pumps can be bulky, restrictive, and clinical-looking. What users want, and expect, is a system that’s simple, discreet, and designed around their lives.

ViCentra, a leading European medical device company, directly addresses this challenge with its Kaleido Insulin Patch Pump System, an insulin patch pump that combines medical precision with personal freedom and modern design.

Today, ViCentra has raised another $13 million, bringing its Series D total to $98 million. The new funds come from ROM Utrecht Region and several Dutch investors, including Venturing Tech, with additional backing from existing supporter Innovation Industries.

The company plans to scale manufacturing and commercial operations across Germany, the Netherlands, and France, while accelerating preparations for the US launch of its next-generation Kaleido system.

Making life with diabetes simpler, more intuitive, and more human

ViCentra was founded in Utrecht by Tim Oakes and Joseph Cefai (who exited the company in 2016) to make life with diabetes easier through thoughtful design and technology that understands users.

The Kaleido insulin patch pump is ViCentra’s flagship product and the cornerstone of its approach. It’s the smallest and lightest insulin patch pump in its class, but what really sets it apart is its design. Users can personalise their pumps with aluminium shells available in ten colours, a design choice meant to reflect individuality rather than medical necessity.

Beyond design, Kaleido integrates with Diabeloop’s hybrid closed-loop systems (DBLG1 and DBLG2), enabling adaptive, automated insulin delivery that adjusts to each user’s needs.

Unlike Insulet’s Omnipod and Tandem Diabetes Care, ViCentra differentiates itself by bridging engineering and design, focusing as much on how the device empowers users as on its medical performance.

What’s next?

Coming off a year in which it doubled its user base to more than 4,000, ViCentra plans to triple its European user community by the end of 2026. The company is also increasing production capacity, expanding its customer support infrastructure, and strengthening its position in key markets, including Germany, alongside the Netherlands and France.


TFN contacted ViCentra for comment regarding diversity and inclusion; no response was received at the time of publication.

Total
0
Shares
Related Posts
Total
0
Share

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner